Representatives from MEPC, the manager and developer of Milton Park, and Immunocore Limited joined construction company Buckingham Group at a ceremonial ‘topping out’ event at 95 Park Drive, Immunocore’s new research laboratory building, on Tuesday 20th March.
Immunocore, a soluble T cell receptor (TCR) company developing first-in-class biologics that have the potential to transform patient lives, is expanding its operations at Milton Park with an additional 53,000 sq ft purpose-built premises, which will help support the Company’s continued growth. As well as 95 Park Drive, Immunocore, which has been based at Milton Park since 2000, currently occupies 165,000 sq ft of laboratory and office space.
Speaking after the event, Philip Campbell, Commercial Director for MEPC at Milton Park said: “Today’s topping out is not only an exciting moment for Immunocore, it is also a milestone in our long-standing commitment to deliver state-of-the-art office and laboratory space for our occupiers. It further bolsters the reputation of Milton Park as a globally significant science and technology hub and part of the most fertile innovation economy in the UK.”,
Andrew Hotchkiss, Chief Executive Officer of Immunocore, added: “This is an exciting time for Immunocore. Our new purpose-built research laboratories will enable us to continue and expand on our ground-breaking research, which we believe will lead to new treatments for cancer and other diseases that will transform the lives of patients. Milton Park is an ideal location, with excellent communication and transport links which are essential for an international business like ours.”
